Thereby, NF-κB inhibitors are potential therapeutic candidates in cancer therapy through stopping tumor cell proliferation, tumor cell death and increasing sensitivity to anti-tumor agents (Escarcega et al., 2007[24]). The gene discussed is NFKB1; the disease is neoplasm.